APA (7th ed.) Citation

Thompson, J. F., Hersey, P., Millward, M., Nathan, P., Chen, W., Venhaus, R., . . . Maraskovsky, E. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Thompson, John F., et al. Results of a Randomized, Double-blind Phase II Clinical Trial of NY-ESO-1 Vaccine with ISCOMATRIX Adjuvant Versus ISCOMATRIX Alone in Participants with High-risk Resected Melanoma. BMJ Publishing Group.

MLA (9th ed.) Citation

Thompson, John F., et al. Results of a Randomized, Double-blind Phase II Clinical Trial of NY-ESO-1 Vaccine with ISCOMATRIX Adjuvant Versus ISCOMATRIX Alone in Participants with High-risk Resected Melanoma. BMJ Publishing Group.